Physicians' Academy for Cardiovascular Education

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD - Glasgow, UK

Video navigation menu

  • Insights from REDUCE-IT and STRENGTH 0:23
  • Overview of potential mechanisms 1:41
  • Focus on lipoprotein synthesis 2:10
  • Focus on plasma lipoproteins 3:12
  • Focus on chronic inflammation 4:37
  • Focus on atherothrombosis 5:56
  • Focus on cell membrane cholesterol 6:46


Show transcript

Educational information

This presentation by Prof. Packard is part of a series titled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".


Prof. Chris Packard, PhD is Honorary Senior Research Fellow at the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, UK.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

Find here the slides of this presentation Listen to the podcast

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: